Combination Ipilimumab/Nivolumab Better Than Single-Agent Anti–PD-1 Regardless of BRAF Status in Advanced Melanoma

Web Exclusives - Melanoma

The combination of ipilimumab (Yervoy) plus nivolumab (Opdivo) appears to be superior to a single-agent PD-1 inhibitor in patients with metastatic melanoma regardless of BRAF mutation status, according to the results of a single-center retrospective analysis of a cohort of more than 300 patients.

The findings run counter to those from the CheckMate-067 trial, which found improved progression-free survival (PFS) and overall survival (OS) with the combination compared with nivolumab alone in patients with BRAF-mutant metastatic melanoma, and no significant difference between the treatments in the BRAF wild-type cohort.

Results of the analysis were presented in poster format by researchers led by Vincent T. Ma, MD, Oncology/Hematology Fellow, University of Michigan, Ann Arbor, during the American Society of Clinical Oncology 2020 Virtual Scientific Program.

“In our analysis, unresectable or metastatic melanoma patients with BRAF wild-type status treated with combination ipilimumab/nivolumab had an increased likelihood of survival compared to patients treated with PD-1 inhibitor,” the investigators concluded.

They identified 323 patients with metastatic or unresectable melanoma diagnosed between 2012 and 2109 at the University of Michigan, 132 with BRAF V600 mutation and 191 with BRAF wild-type disease. A total of 138 patients received ipilimumab/nivolumab and 185 received a PD-1 inhibitor alone.

On univariate analysis, neither PFS (hazard ratio [HR], 0.72; 95% confidence interval [CI], 0.46-1.13) nor OS (HR, 0.78; 95% CI, 0.44-1.38) were significantly different between patients treated with ipilimumab/nivolumab versus a PD-1 inhibitor alone in the BRAF-mutant cohort. However, both PFS (HR, 0.55; 95% CI, 0.35-0.88) and OS (HR, 0.52; 95% CI, 0.28-0.95) were improved in the combination immunotherapy arm versus the monotherapy arm in patients with BRAF wild-type melanoma.

On multivariate analysis, PFS remained significantly superior with the ipilimumab/nivolumab combination versus PD-1 inhibitor monotherapy in the BRAF wild-type cohort (HR, 0.575; 95% CI, 0.35-0.95). The benefit to combination immunotherapy on OS in this subset, however, lost statistical significance (HR, 0.54; 95% CI, 0.28-1.03).

“Due to higher rates of toxicities with ipilimumab/nivolumab, further studies are warranted to identify which patient subgroups may benefit more from combination immunotherapy,” the investigators concluded.

Source: Ma VTL, Daignault S, Waninger J, et al. The impact of BRAF mutation status on clinical outcomes with single-agent PD-1 inhibitor versus combination ipilimumab/nivolumab. J Clin Oncol. 2020;38(15_suppl). Abstract 10024.

Related Items
Novel LAG-3–Blocking Antibody plus Nivolumab Shows Promise as First-Line Treatment in Advanced Melanoma
William King
TON - October 2021 Vol 14, No 5 published on October 14, 2021 in Melanoma
Tebentafusp Improves Survival in Frontline Setting of Metastatic Uveal Melanoma
Patricia Stewart
TOP - September 2021 Vol 14, No 5 published on September 7, 2021 in Melanoma
Real-World Analysis Finds That Dabrafenib/Trametinib Combination Is Effective in Patients with BRAF V600-Mutated Melanoma with Brain Metastases
Web Exclusives published on December 14, 2020 in Melanoma
Effectiveness of Dual Immunotherapy Confirmed for Patients with Metastatic Melanoma and Autoimmune Disease
Web Exclusives published on December 14, 2020 in Melanoma
Symptoms from Immunotherapy/Targeted Therapy Most Mentioned Topic by Patients with Melanoma on Health-Related Social Media
Web Exclusives published on December 14, 2020 in Melanoma
Complete Responses Equally Durable with Shorter versus Longer Immunotherapy Courses in Advanced Melanoma
Web Exclusives published on December 14, 2020 in Melanoma
Meaningful Response Possible with Third-Line Targeted Therapy Rechallenge for Patients with BRAF-Mutation–Positive Advanced Melanoma
Web Exclusives published on November 24, 2020 in Melanoma
Immune-Related Adverse Events Occurring After 2 Years of Anti–PD-1 Therapy Are Common
Web Exclusives published on November 24, 2020 in Melanoma
CheckMate-238 Update: Nivolumab Improves 4-Year Relapse-Free Survival in Patients with Advanced Melanoma
Web Exclusives published on November 24, 2020 in Melanoma
Dabrafenib plus Trametinib Confers Long-Term Relapse-Free Benefit in Stage III BRAF-Mutant Melanoma
Web Exclusives published on November 24, 2020 in Melanoma
Last modified: July 22, 2021